Ribbon

Ribon Therapeutics is a clinical-stage biotechnology company pioneering the discovery and development of first-in-class precision medicines for cancer and inflammatory diseases. The company leverages its proprietary platform to target mono-ADP-ribosyltransferases (MARTs), a family of enzymes that function as critical regulators of cellular stress responses. Ribon's lead candidate, RBN-2397, is a potent and selective small molecule inhibitor of PARP7 currently being evaluated in clinical trials for the treatment of solid tumors. By modulating these stress signaling pathways, Ribon aims to restore health and provide novel therapeutic options for patients with limited treatment alternatives. The company is backed by a premier group of life science investors and maintains strategic collaborations with major pharmaceutical partners.